β-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 6, 2009, Pages 462-467

  Palazzuoli, Alberto ^a   Silverberg, Donald S ^b   Calabrò, Anna ^a   Spinelli, Tommaso ^a   Quatrini, Ilaria ^a   Campagna, Maria S ^a   Franci, Beatrice ^a   Nuti, Ranuccio ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anemia; B type natriuretic peptide; Cardiac function; Chronic heart failure; Erythropoietin; Iron

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; FERROUS GLUCONATE; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ECHOCARDIOGRAPHY; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HEART VENTRICLE VOLUME; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; LUNG ARTERY PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC DYSFUNCTION; TREATMENT DURATION;

ANEMIA; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN, RECOMBINANT; FERROUS COMPOUNDS; HEART FAILURE; HEMATINICS; HOSPITALIZATION; HUMANS; INJECTIONS, SUBCUTANEOUS; NATRIURETIC PEPTIDE, BRAIN; PULMONARY ARTERY; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR REMODELING;

EID: 68249099779     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181a6ac38     Document Type: Article

References (30)

1. Cromie N, Lee C, Struthers AD. Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes? Heart. 2002;87:377-378.
2. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780-1786. (Pubitemid 34595288)
3. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol. 2003;41:1933-1939. (Pubitemid 36677110)
4. Felker GM, Adams KF Jr, Gattis WA, et al. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol. 2004;44:959-966. (Pubitemid 39165127)
5. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107:223-225.
6. Ghali JK, Kadakia S, Cooper R, et al. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med. 1988;148:2013-2016.
7. Tang YD, Katz S. Anemia in chronic heart failure, prevalence etiology clinical correlates, and treatment options. Circulation. 2006;113:2454-2461. (Pubitemid 43948053)
8. Opasich C, Cazzolla M, ScelziL, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as a major cause of anemia in patients with chronic heart failure Eur Heart J. 2005;26:2232-2237.
9. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-1744. (Pubitemid 30342851)
10. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;21:294-299. (Pubitemid 36135227)
11. Palazzuoli A, Silverberg DS, Iovine F, et al. Erythropoietin improves anemia, exercise tolerance, and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152:1096.e9-1096.e15. (Pubitemid 44854798)
12. Ghali JK, Anand IS, Abraham WT, et al. (STAMINA- HeFT group). Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526-535.
13. Schiller NB, Shah PN, Crawford M, et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358-367.
14. DeCara J, Toledo E, Salgo I, et al. Evaluation of left ventricular systolic function using automated angle-independent motion tracking of mitral annular displacement. J Am Soc Echocardiogr. 2005;18:1266-1269. (Pubitemid 41821169)
15. Appleton CP, Hatle LK, Pop RL. Relation of transmitral flow patterns of left diastolic function: new insides from a combined hemodynamic and Doppler echocardiography study. J Am Coll Cardiol. 1998;12:426-440.
16. CM Yu, Sanderson JE, Marwick TH, et al. Tissue Doppler imaging a new prognosticator for cardiovascular diseases. J Am Coll Cardiol. 2007;49: 1903-1914. (Pubitemid 46711162)
17. Linqvist P, Cuclutteea A, Henein M. Echocardiography in the assessment of right heart function. Eur J Echocardiogr. 2008;9:225-234. (Pubitemid 351665195)
18. Palazzuoli A, Gallotta M, Iovine F, et al. Anaemia in heart failure: a common interaction with chronic renal insufficiency called the cardio renal anaemia syndrome. Int J Clin Pract. 2008;62:281-286.
19. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818-827.
20. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775-1780. (Pubitemid 32499958)
21. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alpha on exercise tolerance in anemic patients with symptomatic chronic heart failure. J Am Coll Cardiol. 2007;49:753-762.
22. Kourea K, Parissis JT, Farmakis D, et al. Effect of darbepoetin-alfa on plasma pro-inflammatory cytokines, anti-inflammatory cytokines interleukin-10 and soluble Fas/fas ligand system in anemic patients with chronic heart failure. Atherosclerosis. 2008;199:215-221. (Pubitemid 351842695)
23. Van der meer P, Groenveld H, Januzzi JL, et al. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart. 2009. (In Press).
24. Van Veldhuisen DJ, Mc Murray JJ; RED-HF executive committee. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail. 2007;9:323.
25. Meluzin J, Spinarova L, Hude P, et al. Prognostic importance of various echocardiographic right ventricular parameters in patients with symptomatic heart failure. J Am Soc Echocardiogr. 2005;18:435-444. (Pubitemid 40704582)
26. Ghio S, Recusani F, Klersy C, et al. Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol. 2000;85:837-842. (Pubitemid 30157849)
27. Parissis JT, Kourea K, Panou F, et al. Effect of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J. 2008;155:751e1-751e7.
28. Lipsic E, Westenbrink BD, van der Meer P, et al. Low dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail. 2008;10:22-29.
29. Wright GL, Hanlon P, Amin K, et al. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 2004;25:285-291. (Pubitemid 39561515)
30. van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2005;46:125-133. (Pubitemid 40905140)